As “spin” gains ground, “alternative facts” replace actual facts, and feelings outweigh evidence, real science matters more than ever.
Oxford Dictionaries selected “post-truth” as Word of the Year in 2016 and defined it as “relating to or denoting circumstances in which objective facts are less influential in shaping public opinion than appeals to emotion and personal belief.” It’s become commonplace to assert opinion as fact and stretch the truth. We live in a world where climate change deniers, anti-vaxxers, and flat-earthers receive credibility despite overwhelming evidence disproving their claims.
According to a National Academy of Sciences article, “Distrust in the scientific enterprise and misperceptions of scientific knowledge increasingly stem ... from the widespread dissemination of misleading and biased information.” Such propaganda has created a state of affairs in which self-declared expertise is too often accepted at face value. It’s a bad situation made worse by a bombardment of claims and assertions by companies marketing seemingly science-based consumer products and services.
At Veritas, we’re committed to rooting our products and services in medical and scientific authority. We want not only to share breakthroughs in genomics, but also to explain what they mean — for individuals and for society at large. We want to provide a context for science that is honest, meaningful, and understandable. That’s a huge part of what we mean by “driving accessibility to genomics.” If it’s not clear, it’s not attainable.
One way we’re reinforcing our commitment to clinical and scientific proficiency is by establishing a new Clinical Advisory Board (CAB) of geneticists, researchers, and professors from institutions like Mayo Clinic, Brigham & Women’s Hospital, and the Broad Institute. In addition to our Scientific Advisory Board; CLIA-certified and CAP-accredited laboratory; and team of bioinformaticians, certified genetic counselors, and engineers, our CAB contributes a new layer of credibility and expertise that substantiates our claim to the most comprehensive and clinically-relevant genetic testing service on the market.
“This incredible advisory board was selected to provide expertise that covers all key areas of clinical and consumer genomics across academia and business — aspects of the utmost importance to Veritas. Its members will help us continue leading in our quest to offer clinically-responsible whole genome sequencing.”
– Birgit Funke, PhD, FACMG; Veritas VP of Clinical Affairs
We welcome the following individuals into the Veritas family as our new Clinical Advisory Board:
By continuing to surround ourselves with experts of the highest caliber and renown, we will sustain our efforts to battle and debunk the misinformation and half-truths too often peddled by others in the genetic testing field.